Development Level

Tbio 9 | 11,445
Tchem 6 | 1,598
Tclin 5 | 613

IMPC Phenotype

preweaning lethality, complete... 4 | 979
abnormal behavior 1 | 298
abnormal seminal vesicle morph... 1 | 114
abnormal spleen morphology 1 | 55
abnormal vocalization 1 | 21
decreased bone mineral content 1 | 151
decreased circulating insulin ... 1 | 76
decreased circulating iron lev... 1 | 32
decreased fasted circulating g... 1 | 65
decreased respiratory quotient 1 | 16
decreased startle reflex 1 | 75
enlarged heart 1 | 210
hyperactivity 1 | 148
impaired righting response 1 | 26
increased circulating LDL chol... 1 | 13
increased circulating creatini... 1 | 38
increased circulating triglyce... 1 | 42
male infertility 1 | 123

Disease

Carcinoma 15 | 11,493
Cancer 12 | 2,499
glioblastoma 11 | 5,792
ovarian cancer 11 | 8,520
osteosarcoma 10 | 7,950
atypical teratoid / rhabdoid tumor 9 | 5,112
psoriasis 9 | 6,694
Schizophrenia 8 | 1,160
medulloblastoma, large-cell 8 | 6,241
Breast cancer 7 | 3,578
diabetes mellitus 7 | 1,728
lung carcinoma 7 | 2,843
malignant mesothelioma 7 | 3,232
Depressive disorder 6 | 409
Kidney disease 6 | 430
ependymoma 6 | 4,679
lung cancer 6 | 4,740
Atherosclerosis 5 | 291
Bipolar Disorder 5 | 666
Heart disease 5 | 306
Hypertension 5 | 396
Liver Cirrhosis, Experimental 5 | 769
Mental Depression 5 | 333
Neoplasm Metastasis 5 | 168
cystic fibrosis 5 | 1,696
interstitial cystitis 5 | 2,312
intraductal papillary-mucinous neoplasm (IPMN) 5 | 3,291
invasive ductal carcinoma 5 | 2,951
lung adenocarcinoma 5 | 2,716
non-small cell lung cancer 5 | 2,890
pancreatic cancer 5 | 2,398
subependymal giant cell astrocytoma 5 | 2,287
ulcerative colitis 5 | 1,819
Arthritis 4 | 290
Asthma 4 | 385
Breast Neoplasms 4 | 445
Carcinoma, Squamous Cell 4 | 110
Cerebrovascular disease 4 | 238
Epilepsy 4 | 792
Lung disease 4 | 142
Mammary Neoplasms 4 | 425
Renal Cell Carcinoma 4 | 214
Rheumatoid arthritis 4 | 1,191
Squamous cell carcinoma 4 | 129
Stomach Neoplasms 4 | 300
Substance Withdrawal Syndrome 4 | 55
adult high grade glioma 4 | 3,801
breast carcinoma 4 | 1,638
group 3 medulloblastoma 4 | 4,104
oligodendroglioma 4 | 2,850
pediatric high grade glioma 4 | 1,064
primary pancreatic ductal adenocarcinoma 4 | 1,109
primitive neuroectodermal tumor 4 | 3,035
tuberculosis 4 | 2,010
Adenocarcinoma 3 | 122
Alzheimer's disease 3 | 658
Astrocytoma, Pilocytic 3 | 3,081
Brain Ischemia 3 | 110
Carcinoma of thyroid 3 | 17
Carcinoma, Hepatocellular 3 | 228
Cardiomyopathies 3 | 110
Choreatic disease 3 | 52
Colorectal Neoplasms 3 | 243
Coronary artery disease 3 | 268
Disease Models, Animal 3 | 155
Dystonia 3 | 164
Fetal Growth Retardation 3 | 189
Fibrosis 3 | 44
Gastrointestinal system disease 3 | 54
Gout 3 | 106
Head and Neck Neoplasms 3 | 26
Heart failure 3 | 162
Hemangiosarcoma 3 | 18
Hyperalgesia 3 | 83
Hyperglycemia 3 | 137
Infant, Small for Gestational Age 3 | 176
Intrauterine retardation 3 | 176
Kidney Neoplasm 3 | 29
Kidney Neoplasms 3 | 37
Liver Neoplasms, Experimental 3 | 59
Liver carcinoma 3 | 240
Liver cell carcinoma 3 | 15
Lung Neoplasms 3 | 232
Major Depressive Disorder 3 | 301
Melanoma 3 | 711
Multiple myeloma 3 | 1,332
Neoplasm Invasiveness 3 | 161
Neoplasm Recurrence, Local 3 | 37
Neurodegenerative disease 3 | 414
Obesity 3 | 678
Prostatic Neoplasms 3 | 495
Proteinuria 3 | 144
Seizures 3 | 596
Small head 3 | 374
Vascular disease 3 | 319
Waldenstrons macroglobulinemia 3 | 765
acute quadriplegic myopathy 3 | 1,158
astrocytoma 3 | 1,146
colon cancer 3 | 1,478
intraductal papillary-mucinous adenoma (IPMA) 3 | 2,955

Tissue

Blood and immune system 20 | 16,909
Cardiovascular System 20 | 15,192
Digestive Tract 20 | 17,369
Endocrine System 20 | 18,159
Female tissues 20 | 17,400
Liver and Pancreas 20 | 16,750
Male tissues 20 | 17,142
Nervous System 20 | 16,725
Respiratory system 20 | 16,393
Skin and soft tissues 20 | 17,230
Urinary Tract 20 | 16,678

Target Family

Non-IDG 8 | 12,091
Enzyme 5 | 4,145
Kinase 5 | 634
GPCR 1 | 408
Transporter 1 | 473

PathwayCommons: pid Pathway

http://pathwaycommons.org/pc2/... 20 | 20
http://pathwaycommons.org/pc2/... 137 | 137
http://pathwaycommons.org/pc2/... 125 | 125
http://pathwaycommons.org/pc2/... 102 | 102
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 87 | 87
http://pathwaycommons.org/pc2/... 85 | 85
http://pathwaycommons.org/pc2/... 82 | 82
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 80 | 80
http://pathwaycommons.org/pc2/... 77 | 77
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 74 | 74
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 71 | 71
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 70 | 70
http://pathwaycommons.org/pc2/... 69 | 69
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 67 | 67
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 66 | 66
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 65 | 65
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 64 | 64
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 63 | 63
http://pathwaycommons.org/pc2/... 62 | 62
http://pathwaycommons.org/pc2/... 61 | 61
http://pathwaycommons.org/pc2/... 60 | 60
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 59 | 59
http://pathwaycommons.org/pc2/... 58 | 58
http://pathwaycommons.org/pc2/... 57 | 57
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 56 | 56
http://pathwaycommons.org/pc2/... 55 | 55
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 54 | 54
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 53 | 53
http://pathwaycommons.org/pc2/... 51 | 51
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 50 | 50
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 49 | 49
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 48 | 48
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 47 | 47
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 46 | 46
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 45 | 45
http://pathwaycommons.org/pc2/... 44 | 44
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 43 | 43
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 42 | 42
http://pathwaycommons.org/pc2/... 41 | 41
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 40 | 40
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 39 | 39
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 38 | 38
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 37 | 37
http://pathwaycommons.org/pc2/... 36 | 36

This is where graphics are reside..
Name Gene Development Level Target Family Log Novelty  Pubmed Score  Antibody Count  Knowledge Availability 
Prostaglandin G/H synthase 2 PTGS2 Tclin Enzyme -4.06834 12504.5 731
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-2 PLCB2 Tbio Enzyme -2.14048 137.8 104
Multidrug resistance-associated protein 1 ABCC1 Tchem Transporter -2.81072 662.2 328
Guanine nucleotide-binding protein G(o) subunit alpha GNAO1 Tbio Non-IDG -2.24331 158.7 195
Vascular endothelial growth factor receptor 2 KDR Tclin Kinase -3.67555 4544.8 2373
Mitogen-activated protein kinase 1 MAPK1 Tchem Kinase -3.18822 1239.4 1248
Mitogen-activated protein kinase 3 MAPK3 Tchem Kinase -3.66226 3484.0 1440
Ras-related C3 botulinum toxin substrate 1 RAC1 Tbio Enzyme -1.94674 87.1 452
Sphingosine kinase 1 SPHK1 Tchem Kinase -2.72994 583.6 518
Guanine nucleotide-binding protein G(i) subunit alpha-1 GNAI1 Tbio Non-IDG -0.63224 3.23 220